logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Immunology & Inflammation drugs

    FiltersReset Filters
    53 results

    • actimmune

      (Interferon gamma-1b)
      Horizon Therapeutics USA, Inc.
      Usage: ACTIMMUNE is indicated for reducing serious infections in patients with Chronic Granulomatous Disease (CGD) and for delaying disease progression in severe, malignant osteopetrosis (SMO).

    • alrex

      (loteprednol etabonate)
      Bausch & Lomb Incorporated
      Usage: ALREX ophthalmic suspension is indicated for the temporary relief of signs and symptoms associated with seasonal allergic conjunctivitis.

    • anoro ellipta

      (umeclidinium bromide and vilanterol trifenatate)
      GlaxoSmithKline LLC
      Usage: ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.

    • asceniv

      (HUMAN IMMUNOGLOBULIN G)
      ADMA Biologics, Inc.
      Usage: ASCENIV is indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12-17 years), including conditions such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

    • auvi-q

      (epinephrine)
      kaleo, Inc
      Usage: AUVI-Q® is indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis due to insect stings, food, medications, and other allergens. It is intended for immediate self-administration in individuals at risk for anaphylaxis and is not a substitute for medical care.

    • bepreve

      (bepotastine besilate)
      Bausch & Lomb Incorporated
      Usage: BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is indicated for treating itching linked to allergic conjunctivitis symptoms.

    • biktarvy

      (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
      Gilead Sciences, Inc.
      Usage: BIKTARVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg, either as a complete regimen for those with no antiretroviral treatment history or as a replacement for those who are virologically suppressed on a stable regimen without resistance issues.

    • bivigam

      (Immune Globulin Intravenous (Human) 10%)
      ADMA Biologics, Inc.
      Usage: BIVIGAM is indicated for treating primary humoral immunodeficiency (PI) in adults and children aged 2 years and older. It addresses conditions such as common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

    • cinqair

      (Reslizumab)
      Teva Respiratory, LLC
      Usage: CINQAIR® is indicated as an add-on maintenance treatment for adults (18+) with severe asthma exhibiting an eosinophilic phenotype. It is not intended for other eosinophilic conditions or for acute bronchospasm relief or status asthmaticus.

    • complera

      (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
      Gilead Sciences, Inc.
      Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.